Navigation Links
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Date:11/10/2008

I study is validation of Cell Therapeutics Inc.'s capabilities in acquiring attractive drug candidates, and designing and implementing a successful phase III trial," said James A. Bianco, M.D., CEO of Cell Therapeutics. "These data are consistent with the extensive experience with pixantrone in our phase I and phase II studies and demonstrate the ability to offer patients with advanced, relapsed NHL the potential to obtain a clinically meaningful response like a complete remission, despite having failed multiple other courses of chemotherapy or immuno-chemotherapy."

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission (CR) or unconfirmed complete remission (uCR) rate, overall survival (OS) and progression-free survival (PFS). The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

CTI intends to further evaluate additional details of the study and will provide complete safety and progression-free survival information comparing treatment assignments which is currently being assembled for analysis.

Cell Therapeutics will be presenting at the Rodman & Renshaw Healthcare Conference on November 11, 2008 at 10:45 am Eastern time and a webcast will be available at http://www.celltherapeutics.com.

About Pixantrone

Pixantrone (BBR 2778), a DNA intercalating antit
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
2. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
5. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
6. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
7. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
10. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
11. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... 10, 2011 Sildenafil, a drug used to ... possible use -- helping children and young adults ... Sildenafil significantly improved measures of exercise performance during ... according to researchers from The Children,s Hospital of ...
... seek ways to reduce Medicaid spending, they should start by ... model to the more efficient model used in some parts ... finds that the program could save $473 million over ... more like those in Medicare and commercial plans. Governors Chris ...
Cached Medicine Technology:Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 2Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 3Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2
(Date:7/26/2014)... OH (PRWEB) July 26, 2014 The U.S. ... guidelines list that includes a new medication guide for AndroGel ... a serious side-effect of taking the topical low testosterone medication, ... that AbbVie Inc., the makers of the low testosterone theapy ... symptoms of pain, swelling or redness as signs of a ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... by Vkool.com, this is a comprehensive bodybuilding program that ... without using anabolic steroids . The program also ... muscle without cardio. , Vkool reveals in its ... and workouts that can help men get ripped and ...
(Date:7/26/2014)... July 26, 2014 As the ... the true vision of Xoçai is ... its exclusive and healthy chocolate products. One such ... of cacao, açaí berries and blueberries, an ingredient ... high-antioxidant blend is utilized in all of Xoçai ...
(Date:7/25/2014)... PersonalInjurySolicitorsIreland, a legal claims company that ... have suffered from a variety of injuries, has ... company, and a website, http://www.PersonalInjurySolicitorsIreland.com . , ... http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law firm specialises in ... is always on the client, and everyone is ...
(Date:7/25/2014)... 2014 In recent years, men have become ... reverse the symptoms associated with age-related testosterone decline. Amid concerns ... a new case study from Renew Man helps ... therapy using bioidentical hormones. , The case study centers ... who found himself beginning to feel the effects of age-related ...
Breaking Medicine News(10 mins):Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3
... The number of syphilis cases is increasing among men who ... boost the population's risk of contracting HIV , CDC officials ... the number of syphilis cases in the U.S. reached an ... risen annually from 2000 to 2005, the most recent year ...
... among the senior lot in Australia. This is not a good ... illness or accident. ,A study of 102 patients recuperating ... cent were malnourished. At the same time, the study found that ... reduce their period of stay in the hospital. ...
... excitation through suppressing communication between the cells could be one ... ,Researchers at the University of Bristol seem to ... The SUMO protein acts to damp down the amount of ... level of the protein in the brain could the key ...
... If a leg is to be amputated with no recourse, ... affected leg. Thus stem cells offer immense hope to ... ,Now, scientists have explored the potential of stem ... experiments on animals, it came to light, that special class ...
... a battle between the lesser of two evils or the better ... the world by just one name , is a severely disabled ... disability as well renders her mind akin to a three-month-old baby. ... outlined their treatment and care of their daughter, whom they refer ...
... human body, it is known. But new studies suggest that those ... heart rates, less effective immune systems, surges of stress hormones that ... ,Those who often react to stress by brooding have ... let go of things, shows a new study by psychologist Brenda ...
Cached Medicine News:Health News:Number of Syphilis Cases Rising Among MSM in U.S. 2Health News:British Scientists Discover New Protein to Treat Epilepsy and Schizophrenia 2Health News:Human Rights Activists Sleepless In Seattle 2Health News:Brooding Could Kill, Warn Psychologists 2
For enucleation/evisceration....
... new Transnasal Lacrimal Stent has been introduced by ... M.D., the Transnasal Lacrimal Stent addressed the limitations ... forms of endoscopic DCR. Brought in to position ... diameter. Because there is no need to pass ...
...
... on SIREMOBIL Iso-C, the first truly isocentric ... 3D-Mode, the 3D-dataset is immediately available after ... This allows the surgeon to perform realtime ... procedure. This 3D capability is especially suited ...
Medicine Products: